Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status

Medical Oncology

Volumn 31, Issue 11, 2014, Pages 1-6

  Moriwaki, Toshikazu ^a   Ishige, Kazunori ^a   Araki, Masahiro ^b   Yoshida, Shigemasa ^c   Nishi, Masaaki ^d   Sato, Mikio ^e   Yamada, Takeshi ^a   Yamamoto, Yoshiyuki ^a   Ozeki, Mitsuharu ^b   Ishida, Hiroyasu ^c   Yamaguchi, Takashi ^c   Matsuda, Kenji ^d   Murashita, Tetsuya ^e   Abei, Masato ^a   Hyodo, Ichinosuke ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^d Department of Urology Tsukuba Gakuen Hospital   (Japan)

^e Ryugasaki Saiseikai Hospital   (Japan)

Author keywords

Biliary tract cancer; Chemotherapy; ECOG PS; Glasgow Prognostic Score; Prognostic factor; Stratification factor

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERITONEUM METASTASIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SCORING SYSTEM; BILE DUCT NEOPLASMS; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; HEPATIC DUCT; INTRAHEPATIC BILE DUCT; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84919880760     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0287-y     Document Type: Article

References (18)

1. Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16(1):1–7.
2. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
3. Crumley AB, Stuart RC, McKernan M, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 2):e325–9.
4. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–30.
5. Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;92(10):1834–6.
6. Hwang JE, Kim HN, Kim DE, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 2011;11:489.
7. Iwaku A, Kinoshita A, Onoda H, et al. The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Med Oncol. 2014;31(1):787.
8. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.
9. Oshiro Y, Sasaki R, Fukunaga K, et al. Inflammation-based prognostic score is a useful predictor of postoperative outcome in patients with extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2013;20(3):389–95.
10. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25(13):1670–6.
11. Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(13):1317–25.
12. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
13. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;. doi:10.1016/S1470-2045(14)70330-4.
14. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640–8.
15. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.
16. Morizane C, Okusaka T, Mizusawa J, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104(9):1211–6.
17. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.
18. Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005;35(2):68–73.